Cann Group (ASX:CAN) - CEO Peter Crock
CEO Peter Crock
Source: Cann Group
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Cann Group (CAN) receives $1.2 million in court proceedings as the company seeks to recover funds lost in a cyber security breach earlier this year
  • The medicinal cannabis supplier announced the potential loss of $3.6 million in February after payments to a contractor were intercepted by a third party
  • In March, CAN launched a civil proceeding in Hong Kong aimed at recouping the missing payments
  • The company says criminal investigations are ongoing with no guarantee of any formal prosecutions or further recovery of funds
  • Shares in Cann Group were up by 1.25 per cent at 40.5 cents each at 11:55 am AEST

Cann Group (CAN) has received $1.2 million in court proceedings as the company seeks to recover funds lost in a cyber security breach early this year.

The medicinal cannabis supplier announced the potential loss of $3.6 million in February, after payments intended for an overseas contractor for work on its Milura factory were intercepted by a third party.

At the time, Cann quickly began working with its bank to determine whether any of the funds could be recovered. Insurance brokers were also onboarded to determine whether a claim could be made to cover the loss.

A review of the company’s IT systems aimed to identify any contributing issues.

In March, Cann subsequently commenced a civil proceeding in Hong Kong seeking to recover the missing payments.

The company has updated the market on its progress this morning, saying criminal investigations are continuing in various jurisdictions.

Even so, there is reportedly no guarantee that any formal prosecutions will arise from the action, nor that any further funds will be recovered.

Following the announcement, shares in Cann Group were trading 1.25 per cent higher at 40.5 cents each at 11:55 am AEST.

CAN by the numbers
More From The Market Online

Inoviq closes the gap on blood test results for ovarian cancer

INOVIQ has announced encouraging blood test identification results for ovarian cancer – cancer-positive tests saw a…

Paradigm Biopharma on track to US Phase III osteo program

Paradigm Biopharma has announced its completion of a submission to the US FDA to progress to…

Firebrick Pharma’s US launch of Nasal Spray is nothing to be sneezed at

Australian pharmaceutical developer, Firebrick Pharma (ASX:FRE) has launched its latest product, Nasodine Nasal Spray, in the…